Divergent quality-of-life results from two glioblastoma studies of Avastin (bevacizumab) could complicate Genentech Inc.’s regulatory prospects for expanding the VEGF inhibitor’s use to the first-line setting.
The mixed data from two Phase III studies – one sponsored by parent company Roche, the other by the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?